BioCryst Pharmaceuticals ...

NASDAQ: BCRX · Real-Time Price · USD
8.31
0.03 (0.36%)
At close: Aug 20, 2025, 9:46 AM

BioCryst Pharmaceuticals Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-88.88M -226.54M -247.12M -184.06M
Depreciation & Amortization
1.25M 1.66M 1.44M 777K
Stock-Based Compensation
65.41M 55.62M 44.7M 34.64M
Other Working Capital
1.96M -8.05M -2.69M 1.28M
Other Non-Cash Items
57.48M 106.53M 98.07M -1.64M
Deferred Income Tax
n/a n/a n/a -55.84M
Change in Working Capital
-87.28M -32.4M -58.95M 8.12M
Operating Cash Flow
-52.02M -95.14M -161.85M -142.16M
Capital Expenditures
-1.12M -2.17M -1.35M -2.38M
Cash Acquisitions
n/a n/a 1.35M 2.38M
Purchase of Investments
-266.76M -514.41M -244.28M -10.01M
Sales Maturities Of Investments
320.48M 385.08M 117.4M 28.2M
Other Investing Acitivies
n/a n/a -1.35M n/a
Investing Cash Flow
52.59M -131.5M -128.24M 15.8M
Debt Repayment
-1.7M 58.38M 73.07M 293.87M
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
-4.09M -25.9M 14.77M 15.73M
Financial Cash Flow
-5.76M 32.48M 88.03M 359.67M
Net Cash Flow
-6.12M -193.79M -201.5M 233.39M
Free Cash Flow
-53.14M -97.31M -163.2M -144.54M